

Global Neulasta (Pegfilgrastim) and Biosimilar Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

<https://marketpublishers.com/r/G0056669A1B2EN.html>

Date: June 2023

Pages: 95

Price: US\$ 3,480.00 (Single User License)

ID: G0056669A1B2EN

Abstracts

According to our (Global Info Research) latest study, the global Neulasta (Pegfilgrastim) and Biosimilar market size was valued at USD 2501.4 million in 2022 and is forecast to a readjusted size of USD 3816.3 million by 2029 with a CAGR of 6.2% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analog filgrastim. It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed by Amgen.

This report is a detailed and comprehensive analysis for global Neulasta (Pegfilgrastim) and Biosimilar market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Neulasta (Pegfilgrastim) and Biosimilar market size and forecasts, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Neulasta (Pegfilgrastim) and Biosimilar market size and forecasts by region and country, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Neulasta (Pegfilgrastim) and Biosimilar market size and forecasts, by Type and by Application, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Neulasta (Pegfilgrastim) and Biosimilar market shares of main players, shipments in revenue (\$ Million), sales quantity (K Units), and ASP (US\$/Unit), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Neulasta (Pegfilgrastim) and Biosimilar

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Neulasta (Pegfilgrastim) and Biosimilar market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Viatrix, Coherus, Novartis and Pfizer, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market Segmentation

Neulasta (Pegfilgrastim) and Biosimilar market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Brand

Biosimilar

Market segment by Application

Hospital

Pharmacy

Other

Major players covered

Amgen

Viartis

Coherus

Novartis

Pfizer

Amneal Pharmaceutical

Fresenius Kabi

Market segment by region, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Neulasta (Pegfilgrastim) and Biosimilar product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Neulasta (Pegfilgrastim) and Biosimilar, with price, sales, revenue and global market share of Neulasta (Pegfilgrastim) and Biosimilar from 2018 to 2023.

Chapter 3, the Neulasta (Pegfilgrastim) and Biosimilar competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Neulasta (Pegfilgrastim) and Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022. and Neulasta (Pegfilgrastim) and Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.

Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.

Chapter 13, the key raw materials and key suppliers, and industry chain of Neulasta (Pegfilgrastim) and Biosimilar.

Chapter 14 and 15, to describe Neulasta (Pegfilgrastim) and Biosimilar sales channel, distributors, customers, research findings and conclusion.

Contents

1 MARKET OVERVIEW

- 1.1 Product Overview and Scope of Neulasta (Pegfilgrastim) and Biosimilar
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
 - 1.3.1 Overview: Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Type: 2018 Versus 2022 Versus 2029
 - 1.3.2 Brand
 - 1.3.3 Biosimilar
- 1.4 Market Analysis by Application
 - 1.4.1 Overview: Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Application: 2018 Versus 2022 Versus 2029
 - 1.4.2 Hospital
 - 1.4.3 Pharmacy
 - 1.4.4 Other
- 1.5 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size & Forecast
 - 1.5.1 Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value (2018 & 2022 & 2029)
 - 1.5.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity (2018-2029)
 - 1.5.3 Global Neulasta (Pegfilgrastim) and Biosimilar Average Price (2018-2029)

2 MANUFACTURERS PROFILES

- 2.1 Amgen
 - 2.1.1 Amgen Details
 - 2.1.2 Amgen Major Business
 - 2.1.3 Amgen Neulasta (Pegfilgrastim) and Biosimilar Product and Services
 - 2.1.4 Amgen Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.1.5 Amgen Recent Developments/Updates
- 2.2 Viatris
 - 2.2.1 Viatris Details
 - 2.2.2 Viatris Major Business
 - 2.2.3 Viatris Neulasta (Pegfilgrastim) and Biosimilar Product and Services
 - 2.2.4 Viatris Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.2.5 Viatris Recent Developments/Updates

2.3 Coherus

2.3.1 Coherus Details

2.3.2 Coherus Major Business

2.3.3 Coherus Neulasta (Pegfilgrastim) and Biosimilar Product and Services

2.3.4 Coherus Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)

2.3.5 Coherus Recent Developments/Updates

2.4 Novartis

2.4.1 Novartis Details

2.4.2 Novartis Major Business

2.4.3 Novartis Neulasta (Pegfilgrastim) and Biosimilar Product and Services

2.4.4 Novartis Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)

2.4.5 Novartis Recent Developments/Updates

2.5 Pfizer

2.5.1 Pfizer Details

2.5.2 Pfizer Major Business

2.5.3 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product and Services

2.5.4 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)

2.5.5 Pfizer Recent Developments/Updates

2.6 Amneal Pharmaceutical

2.6.1 Amneal Pharmaceutical Details

2.6.2 Amneal Pharmaceutical Major Business

2.6.3 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product and Services

2.6.4 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)

2.6.5 Amneal Pharmaceutical Recent Developments/Updates

2.7 Fresenius Kabi

2.7.1 Fresenius Kabi Details

2.7.2 Fresenius Kabi Major Business

2.7.3 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product and Services

2.7.4 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)

2.7.5 Fresenius Kabi Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR BY MANUFACTURER

3.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Manufacturer (2018-2023)

3.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Manufacturer (2018-2023)

3.3 Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Manufacturer (2018-2023)

3.4 Market Share Analysis (2022)

3.4.1 Producer Shipments of Neulasta (Pegfilgrastim) and Biosimilar by Manufacturer Revenue (\$MM) and Market Share (%): 2022

3.4.2 Top 3 Neulasta (Pegfilgrastim) and Biosimilar Manufacturer Market Share in 2022

3.4.2 Top 6 Neulasta (Pegfilgrastim) and Biosimilar Manufacturer Market Share in 2022

3.5 Neulasta (Pegfilgrastim) and Biosimilar Market: Overall Company Footprint Analysis

3.5.1 Neulasta (Pegfilgrastim) and Biosimilar Market: Region Footprint

3.5.2 Neulasta (Pegfilgrastim) and Biosimilar Market: Company Product Type Footprint

3.5.3 Neulasta (Pegfilgrastim) and Biosimilar Market: Company Product Application Footprint

3.6 New Market Entrants and Barriers to Market Entry

3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

4.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region

4.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Region (2018-2029)

4.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Region (2018-2029)

4.1.3 Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Region (2018-2029)

4.2 North America Neulasta (Pegfilgrastim) and Biosimilar Consumption Value (2018-2029)

4.3 Europe Neulasta (Pegfilgrastim) and Biosimilar Consumption Value (2018-2029)

4.4 Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Consumption Value (2018-2029)

4.5 South America Neulasta (Pegfilgrastim) and Biosimilar Consumption Value (2018-2029)

4.6 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Consumption Value

(2018-2029)

5 MARKET SEGMENT BY TYPE

5.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2018-2029)

5.2 Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Type
(2018-2029)

5.3 Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Type (2018-2029)

6 MARKET SEGMENT BY APPLICATION

6.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application
(2018-2029)

6.2 Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Application
(2018-2029)

6.3 Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Application
(2018-2029)

7 NORTH AMERICA

7.1 North America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type
(2018-2029)

7.2 North America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application
(2018-2029)

7.3 North America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country

7.3.1 North America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Country
(2018-2029)

7.3.2 North America Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by
Country (2018-2029)

7.3.3 United States Market Size and Forecast (2018-2029)

7.3.4 Canada Market Size and Forecast (2018-2029)

7.3.5 Mexico Market Size and Forecast (2018-2029)

8 EUROPE

8.1 Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2018-2029)

8.2 Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application
(2018-2029)

8.3 Europe Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country

8.3.1 Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Country (2018-2029)

8.3.2 Europe Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Country (2018-2029)

8.3.3 Germany Market Size and Forecast (2018-2029)

8.3.4 France Market Size and Forecast (2018-2029)

8.3.5 United Kingdom Market Size and Forecast (2018-2029)

8.3.6 Russia Market Size and Forecast (2018-2029)

8.3.7 Italy Market Size and Forecast (2018-2029)

9 ASIA-PACIFIC

9.1 Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2018-2029)

9.2 Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application (2018-2029)

9.3 Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region

9.3.1 Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Region (2018-2029)

9.3.2 Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Region (2018-2029)

9.3.3 China Market Size and Forecast (2018-2029)

9.3.4 Japan Market Size and Forecast (2018-2029)

9.3.5 Korea Market Size and Forecast (2018-2029)

9.3.6 India Market Size and Forecast (2018-2029)

9.3.7 Southeast Asia Market Size and Forecast (2018-2029)

9.3.8 Australia Market Size and Forecast (2018-2029)

10 SOUTH AMERICA

10.1 South America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2018-2029)

10.2 South America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application (2018-2029)

10.3 South America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country

10.3.1 South America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Country (2018-2029)

10.3.2 South America Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Country (2018-2029)

- 10.3.3 Brazil Market Size and Forecast (2018-2029)
- 10.3.4 Argentina Market Size and Forecast (2018-2029)

11 MIDDLE EAST & AFRICA

- 11.1 Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2018-2029)
- 11.2 Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application (2018-2029)
- 11.3 Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country
 - 11.3.1 Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Country (2018-2029)
 - 11.3.2 Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Country (2018-2029)
 - 11.3.3 Turkey Market Size and Forecast (2018-2029)
 - 11.3.4 Egypt Market Size and Forecast (2018-2029)
 - 11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
 - 11.3.6 South Africa Market Size and Forecast (2018-2029)

12 MARKET DYNAMICS

- 12.1 Neulasta (Pegfilgrastim) and Biosimilar Market Drivers
- 12.2 Neulasta (Pegfilgrastim) and Biosimilar Market Restraints
- 12.3 Neulasta (Pegfilgrastim) and Biosimilar Trends Analysis
- 12.4 Porters Five Forces Analysis
 - 12.4.1 Threat of New Entrants
 - 12.4.2 Bargaining Power of Suppliers
 - 12.4.3 Bargaining Power of Buyers
 - 12.4.4 Threat of Substitutes
 - 12.4.5 Competitive Rivalry
- 12.5 Influence of COVID-19 and Russia-Ukraine War
 - 12.5.1 Influence of COVID-19
 - 12.5.2 Influence of Russia-Ukraine War

13 RAW MATERIAL AND INDUSTRY CHAIN

- 13.1 Raw Material of Neulasta (Pegfilgrastim) and Biosimilar and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Neulasta (Pegfilgrastim) and Biosimilar

13.3 Neulasta (Pegfilgrastim) and Biosimilar Production Process

13.4 Neulasta (Pegfilgrastim) and Biosimilar Industrial Chain

14 SHIPMENTS BY DISTRIBUTION CHANNEL

14.1 Sales Channel

14.1.1 Direct to End-User

14.1.2 Distributors

14.2 Neulasta (Pegfilgrastim) and Biosimilar Typical Distributors

14.3 Neulasta (Pegfilgrastim) and Biosimilar Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

16.1 Methodology

16.2 Research Process and Data Source

16.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Table 2. Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029

Table 3. Amgen Basic Information, Manufacturing Base and Competitors

Table 4. Amgen Major Business

Table 5. Amgen Neulasta (Pegfilgrastim) and Biosimilar Product and Services

Table 6. Amgen Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 7. Amgen Recent Developments/Updates

Table 8. Viatris Basic Information, Manufacturing Base and Competitors

Table 9. Viatris Major Business

Table 10. Viatris Neulasta (Pegfilgrastim) and Biosimilar Product and Services

Table 11. Viatris Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 12. Viatris Recent Developments/Updates

Table 13. Coherus Basic Information, Manufacturing Base and Competitors

Table 14. Coherus Major Business

Table 15. Coherus Neulasta (Pegfilgrastim) and Biosimilar Product and Services

Table 16. Coherus Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 17. Coherus Recent Developments/Updates

Table 18. Novartis Basic Information, Manufacturing Base and Competitors

Table 19. Novartis Major Business

Table 20. Novartis Neulasta (Pegfilgrastim) and Biosimilar Product and Services

Table 21. Novartis Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 22. Novartis Recent Developments/Updates

Table 23. Pfizer Basic Information, Manufacturing Base and Competitors

Table 24. Pfizer Major Business

Table 25. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product and Services

Table 26. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 27. Pfizer Recent Developments/Updates

Table 28. Amneal Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 29. Amneal Pharmaceutical Major Business

Table 30. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product and Services

Table 31. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 32. Amneal Pharmaceutical Recent Developments/Updates

Table 33. Fresenius Kabi Basic Information, Manufacturing Base and Competitors

Table 34. Fresenius Kabi Major Business

Table 35. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product and Services

Table 36. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 37. Fresenius Kabi Recent Developments/Updates

Table 38. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Manufacturer (2018-2023) & (K Units)

Table 39. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Manufacturer (2018-2023) & (USD Million)

Table 40. Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Manufacturer (2018-2023) & (US\$/Unit)

Table 41. Market Position of Manufacturers in Neulasta (Pegfilgrastim) and Biosimilar, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022

Table 42. Head Office and Neulasta (Pegfilgrastim) and Biosimilar Production Site of Key Manufacturer

Table 43. Neulasta (Pegfilgrastim) and Biosimilar Market: Company Product Type Footprint

Table 44. Neulasta (Pegfilgrastim) and Biosimilar Market: Company Product Application Footprint

Table 45. Neulasta (Pegfilgrastim) and Biosimilar New Market Entrants and Barriers to Market Entry

Table 46. Neulasta (Pegfilgrastim) and Biosimilar Mergers, Acquisition, Agreements, and Collaborations

Table 47. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Region

(2018-2023) & (K Units)

Table 48. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)

Table 49. Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)

Table 50. Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)

Table 51. Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Region (2018-2023) & (US\$/Unit)

Table 52. Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Region (2024-2029) & (US\$/Unit)

Table 53. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)

Table 54. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 55. Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Type (2018-2023) & (USD Million)

Table 56. Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Type (2024-2029) & (USD Million)

Table 57. Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Type (2018-2023) & (US\$/Unit)

Table 58. Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Type (2024-2029) & (US\$/Unit)

Table 59. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 60. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 61. Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Application (2018-2023) & (USD Million)

Table 62. Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Application (2024-2029) & (USD Million)

Table 63. Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Application (2018-2023) & (US\$/Unit)

Table 64. Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Application (2024-2029) & (US\$/Unit)

Table 65. North America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)

Table 66. North America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 67. North America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 68. North America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 69. North America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)

Table 70. North America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)

Table 71. North America Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)

Table 72. North America Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)

Table 73. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)

Table 74. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 75. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 76. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 77. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)

Table 78. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)

Table 79. Europe Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)

Table 80. Europe Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)

Table 81. Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)

Table 82. Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 83. Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 84. Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 85. Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)

Table 86. Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Region

(2024-2029) & (K Units)

Table 87. Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)

Table 88. Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)

Table 89. South America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)

Table 90. South America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 91. South America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 92. South America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 93. South America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)

Table 94. South America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)

Table 95. South America Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)

Table 96. South America Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)

Table 97. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)

Table 98. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 99. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 100. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 101. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)

Table 102. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)

Table 103. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)

Table 104. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)

Table 105. Neulasta (Pegfilgrastim) and Biosimilar Raw Material

Table 106. Key Manufacturers of Neulasta (Pegfilgrastim) and Biosimilar Raw Materials

Table 107. Neulasta (Pegfilgrastim) and Biosimilar Typical Distributors

Table 108. Neulasta (Pegfilgrastim) and Biosimilar Typical Customers

List Of Figures

LIST OF FIGURES

- Figure 1. Neulasta (Pegfilgrastim) and Biosimilar Picture
- Figure 2. Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
- Figure 3. Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value Market Share by Type in 2022
- Figure 4. Brand Examples
- Figure 5. Biosimilar Examples
- Figure 6. Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
- Figure 7. Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value Market Share by Application in 2022
- Figure 8. Hospital Examples
- Figure 9. Pharmacy Examples
- Figure 10. Other Examples
- Figure 11. Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value, (USD Million): 2018 & 2022 & 2029
- Figure 12. Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value and Forecast (2018-2029) & (USD Million)
- Figure 13. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity (2018-2029) & (K Units)
- Figure 14. Global Neulasta (Pegfilgrastim) and Biosimilar Average Price (2018-2029) & (US\$/Unit)
- Figure 15. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity Market Share by Manufacturer in 2022
- Figure 16. Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value Market Share by Manufacturer in 2022
- Figure 17. Producer Shipments of Neulasta (Pegfilgrastim) and Biosimilar by Manufacturer Sales Quantity (\$MM) and Market Share (%): 2021
- Figure 18. Top 3 Neulasta (Pegfilgrastim) and Biosimilar Manufacturer (Consumption Value) Market Share in 2022
- Figure 19. Top 6 Neulasta (Pegfilgrastim) and Biosimilar Manufacturer (Consumption Value) Market Share in 2022
- Figure 20. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity Market Share by Region (2018-2029)
- Figure 21. Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value Market

Share by Region (2018-2029)

Figure 22. North America Neulasta (Pegfilgrastim) and Biosimilar Consumption Value (2018-2029) & (USD Million)

Figure 23. Europe Neulasta (Pegfilgrastim) and Biosimilar Consumption Value (2018-2029) & (USD Million)

Figure 24. Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Consumption Value (2018-2029) & (USD Million)

Figure 25. South America Neulasta (Pegfilgrastim) and Biosimilar Consumption Value (2018-2029) & (USD Million)

Figure 26. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Consumption Value (2018-2029) & (USD Million)

Figure 27. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity Market Share by Type (2018-2029)

Figure 28. Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value Market Share by Type (2018-2029)

Figure 29. Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Type (2018-2029) & (US\$/Unit)

Figure 30. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity Market Share by Application (2018-2029)

Figure 31. Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value Market Share by Application (2018-2029)

Figure 32. Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Application (2018-2029) & (US\$/Unit)

Figure 33. North America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity Market Share by Type (2018-2029)

Figure 34. North America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity Market Share by Application (2018-2029)

Figure 35. North America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity Market Share by Country (2018-2029)

Figure 36. North America Neulasta (Pegfilgrastim) and Biosimilar Consumption Value Market Share by Country (2018-2029)

Figure 37. United States Neulasta (Pegfilgrastim) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 38. Canada Neulasta (Pegfilgrastim) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 39. Mexico Neulasta (Pegfilgrastim) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 40. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity Market Share by Type (2018-2029)

Figure 41. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity Market Share by Application (2018-2029)

Figure 42. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity Market Share by Country (2018-2029)

Figure 43. Europe Neulasta (Pegfilgrastim) and Biosimilar Consumption Value Market Share by Country (2018-2029)

Figure 44. Germany Neulasta (Pegfilgrastim) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 45. France Neulasta (Pegfilgrastim) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 46. United Kingdom Neulasta (Pegfilgrastim) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 47. Russia Neulasta (Pegfilgrastim) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 48. Italy Neulasta (Pegfilgrastim) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 49. Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity Market Share by Type (2018-2029)

Figure 50. Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity Market Share by Application (2018-2029)

Figure 51. Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity Market Share by Region (2018-2029)

Figure 52. Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Consumption Value Market Share by Region (2018-2029)

Figure 53. China Neulasta (Pegfilgrastim) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 54. Japan Neulasta (Pegfilgrastim) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 55. Korea Neulasta (Pegfilgrastim) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 56. India Neulasta (Pegfilgrastim) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 57. Southeast Asia Neulasta (Pegfilgrastim) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 58. Australia Neulasta (Pegfilgrastim) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 59. South America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity Market Share by Type (2018-2029)

Figure 60. South America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity Market

Share by Application (2018-2029)

Figure 61. South America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity Market Share by Country (2018-2029)

Figure 62. South America Neulasta (Pegfilgrastim) and Biosimilar Consumption Value Market Share by Country (2018-2029)

Figure 63. Brazil Neulasta (Pegfilgrastim) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 64. Argentina Neulasta (Pegfilgrastim) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 65. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity Market Share by Type (2018-2029)

Figure 66. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity Market Share by Application (2018-2029)

Figure 67. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity Market Share by Region (2018-2029)

Figure 68. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Consumption Value Market Share by Region (2018-2029)

Figure 69. Turkey Neulasta (Pegfilgrastim) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 70. Egypt Neulasta (Pegfilgrastim) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 71. Saudi Arabia Neulasta (Pegfilgrastim) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 72. South Africa Neulasta (Pegfilgrastim) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 73. Neulasta (Pegfilgrastim) and Biosimilar Market Drivers

Figure 74. Neulasta (Pegfilgrastim) and Biosimilar Market Restraints

Figure 75. Neulasta (Pegfilgrastim) and Biosimilar Market Trends

Figure 76. Porters Five Forces Analysis

Figure 77. Manufacturing Cost Structure Analysis of Neulasta (Pegfilgrastim) and Biosimilar in 2022

Figure 78. Manufacturing Process Analysis of Neulasta (Pegfilgrastim) and Biosimilar

Figure 79. Neulasta (Pegfilgrastim) and Biosimilar Industrial Chain

Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors

Figure 81. Direct Channel Pros & Cons

Figure 82. Indirect Channel Pros & Cons

Figure 83. Methodology

Figure 84. Research Process and Data Source

I would like to order

Product name: Global Neulasta (Pegfilgrastim) and Biosimilar Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Product link: <https://marketpublishers.com/r/G0056669A1B2EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0056669A1B2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

